Structural heterogeneity and multifunctionality of lactoferrin

Current Protein and Peptide Science

Volumn 15, Issue 8, 2014, Pages 778-797

  Albar, Abdulgader H ^a   Almehdar, Hussein A ^a   Uversky, Vladimir N ^a,b,c   Redwan, Elrashdy M ^a,d  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c INSTITUTE FOR BIOLOGICAL INSTRUMENTATION   (Russian Federation)

^d City of Scientific Research and Technological Applications   (Egypt)

Author keywords

Antimicrobial; Antiviral; Glycoprotein; Heterogeneity; Iron binding; Lactoferrin

Indexed keywords

CD81 ANTIGEN; GLYCOPROTEIN E2; HEPARIN; LACTOFERRIN; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT;

ALTERNATIVE RNA SPLICING; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BREAST MILK; CRYSTAL STRUCTURE; ENZYME ACTIVITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOMODULATION; INNATE IMMUNITY; LACTATION; LIVER CELL CARCINOMA; PROTEIN DNA INTERACTION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN POLYMORPHISM; PROTEIN PROCESSING; PROTEIN RNA BINDING; PROTEIN STRUCTURE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; ROSS RIVER ALPHA VIRUS; VESIVIRUS; VIREMIA; VIRUS INFECTION; VISUAL IMPAIRMENT; WART VIRUS; WOUND HEALING; X RAY DIFFRACTION; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; GENETICS; GLYCOSYLATION; METABOLISM; MOLECULAR GENETICS;

MAMMALIA;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; GLYCOSYLATION; HUMANS; LACTOFERRIN; MOLECULAR SEQUENCE DATA;

EID: 84919727700     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/1389203715666140919124530     Document Type: Article

References (263)

1. Walzem, R. L.; Dillard, C. J.; German, J. B. Whey components: millennia of evolution create functionalities for mammalian nutrition: what we know and what we may be overlooking. Crit. Rev. Food Sci. Nutr., 2002, 42, 353-375.
2. Marshall, K. Therapeutic applications of whey protein. Altern. Med. Rev., 2004, 9, 136-156.
3. Legrand, D.; Pierce, A.; Elass, E.; Carpentier, M.; Mariller, C.; Mazurier, J. Lactoferrin structure and functions. Adv. Exp. Med. Biol., 2008, 606, 163-194.
4. Lonnerdal, B. Nutritional roles of lactoferrin. Curr. Opin. Clin. Nutr. Metab. Care, 2009, 12, 293-297.
5. Hanson, L. A.; Korotkova, M. The role of breastfeeding in prevention of neonatal infection. Semin. Neonatol., 2002, 7, 275-281.
6. Rey, M. W.; Woloshuk, S. L.; deBoer, H. A.; Pieper, F. R. Complete nucleotide sequence of human mammary gland lactoferrin. Nucleic Acids Res., 1990, 18, 5288.
7. Pierce, A.; Colavizza, D.; Benaissa, M.; Maes, P.; Tartar, A.; Montreuil, J.; Spik, G. Molecular cloning and sequence analysis of bovine lactotransferrin. Eur. J. Biochem., 1991, 196, 177-184.
8. Spik, G.; Coddeville, B.; Mazurier, J.; Bourne, Y.; Cambillaut, C.; Montreuil, J. Primary and three-dimensional structure of lactotransferrin (lactoferrin) glycans. Adv. Exp. Med. Biol., 1994, 357, 21-32.
9. van Berkel, P. H.; Geerts, M. E.; van Veen, H. A.; Kooiman, P. M.; Pieper, F. R.; de Boer, H. A.; Nuijens, J. H. Glycosylated and unglycosylated human lactoferrins both bind iron and show identical affinities towards human lysozyme and bacterial lipopolysaccharide, but differ in their susceptibilities towards tryptic proteolysis. Biochem. J., 1995, 312(Pt 1), 107-114.
10. van Berkel, P. H.; van Veen, H. A.; Geerts, M. E.; de Boer, H. A.; Nuijens, J. H. Heterogeneity in utilization of N-glycosylation sites Asn624 and Asn138 in human lactoferrin: a study with glycosylation-site mutants. Biochem. J., 1996, 319(Pt 1), 117-122.
11. Wei, Z.; Nishimura, T.; Yoshida, S. Characterization of glycans in a lactoferrin isoform, lactoferrin-a. J. Dairy Sci., 2001, 84, 2584-2590.
12. van Veen, H. A.; Geerts, M. E.; van Berkel, P. H.; Nuijens, J. H. The role of N-linked glycosylation in the protection of human and bovine lactoferrin against tryptic proteolysis. Eur. J. Biochem., 2004, 271, 678-684.
13. Wei, Z.; Nishimura, T.; Yoshida, S. Presence of a glycan at a potential N-glycosylation site, Asn-281, of bovine lactoferrin. J. Dairy. Sci., 2000, 83, 683-689.
14. Yoshida, S.; Wei, Z.; Shinmura, Y.; Fukunaga, N. Separation of lactoferrin-a and-b from bovine colostrum. J. Dairy. Sci., 2000, 83, 2211-2215.
15. van Veen, H. A.; Geerts, M. E.; van Berkel, P. H.; Nuijens, J. H. Analytical cation-exchange chromatography to assess the identity, purity, and N-terminal integrity of human lactoferrin. Anal. Biochem., 2002, 309, 60-66.
16. Kapeller, S. R.; Ackermann, M.; Farah, Z.; Puhan, Z. Sequence analysis of camel (Camelus dromedarius) lactoferrin. Int. Dairy J., 1999, 9, 481-486.
17. Ziere, G. J.; Bijsterbosch, M. K.; van Berkel, T. J. Removal of 14 Nterminal amino acids of lactoferrin enhances its affinity for parenchymal liver cells and potentiates the inhibition of beta-very low density lipoprotein binding. J. Biol. Chem., 1993, 268, 27069-27075.
18. Baker, H. M.; Baker, E. N. A structural perspective on lactoferrin function. Biochem. Cell Biol., 2012, 90, 320-328.
19. Sambrook, J. Adenovirus amazes at Cold Spring Harbor. Nature, 1977, 268, 101-104.
20. Black, D. L. Mechanisms of alternative pre-messenger RNA splicing. Annu. Rev. Biochem., 2003, 72, 291-336.
21. Siebert, P. D.; Huang, B. C. Identification of an alternative form of human lactoferrin mRNA that is expressed differentially in normal tissues and tumor-derived cell lines. Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 2198-2203.
22. Mariller, C.; Hardiville, S.; Hoedt, E.; Huvent, I.; Pina-Canseco, S.; Pierce, A. Delta-lactoferrin, an intracellular lactoferrin isoform that acts as a transcription factor. Biochem. Cell Biol., 2012, 90, 307-319.
23. Kappeler, S.; Farah, Z.; Puhan, Z. Alternative splicing of lactophorin mRNA from lactating mammary gland of the camel (Camelus dromedarius). J. Dairy Sci., 1999, 82, 2084-2093.
24. Breton, M.; Mariller, C.; Benaissa, M.; Caillaux, K.; Browaeys, E.; Masson, M.; Vilain, J. P.; Mazurier, J.; Pierce, A. Expression of delta-lactoferrin induces cell cycle arrest. Biometals, 2004, 17, 325-329.
25. Liu, D.; Wang, X.; Zhang, Z.; Teng, C. T. An intronic alternative promoter of the human lactoferrin gene is activated by Ets. Biochem. Biophys. Res. Commun., 2003, 301, 472-479.
26. Benaissa, M.; Peyrat, J. P.; Hornez, L.; Mariller, C.; Mazurier, J.; Pierce, A. Expression and prognostic value of lactoferrin mRNA isoforms in human breast cancer. Int. J. Cancer, 2005, 114, 299-306.
27. Hoedt, E.; Hardiville, S.; Mariller, C.; Elass, E.; Perraudin, J. P.; Pierce, A. Discrimination and evaluation of lactoferrin and deltalactoferrin gene expression levels in cancer cells and under inflammatory stimuli using TaqMan real-time PCR. Biometals, 2010, 23, 441-452.
28. Mariller, C.; Benaissa, M.; Hardiville, S.; Breton, M.; Pradelle, G.; Mazurier, J.; Pierce, A. Human delta-lactoferrin is a transcription factor that enhances Skp1 (S-phase kinase-associated protein) gene expression. FEBS J., 2007, 274, 2038-2053.
29. Mariller, C.; Hardiville, S.; Hoedt, E.; Benaissa, M.; Mazurier, J.; Pierce, A. Proteomic approach to the identification of novel deltalactoferrin target genes: Characterization of DcpS, an mRNA scavenger decapping enzyme. Biochimie., 2009, 91, 109-122.
30. Levay, P. F.; Viljoen, M. Lactoferrin: a general review. Haematologica, 1995, 80, 252-267.
31. Metz-Boutigue, M. H.; Jolles, J.; Mazurier, J.; Schoentgen, F.; Legrand, D.; Spik, G.; Montreuil, J.; Jolles, P. Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. Eur. J. Biochem., 1984, 145, 659-676.
32. Legrand, D.; Mazurier, J.; Metz-Boutigue, M. H.; Jolles, J.; Jolles, P.; Montreuil, J.; Spik, G. Characterization and localization of an iron-binding 18-kDa glycopeptide isolated from the N-terminal half of human lactotransferrin. Biochim. Biophys. Acta., 1984, 787, 90-96.
33. Mazurier, J.; Lhoste, J. M.; Montreuil, J.; Spik, G. Comparative study of the iron-binding properties of human transferrins. II. Electron paramagnetic resonance of mixed metal complexes of human lactotransferrin. Biochim. Biophys. Acta., 1983, 745, 44-49.
34. Mazurier, J.; Spik, G. Comparative study of the iron-binding properties of human transferrins. I. Complete and sequential iron saturation and desaturation of the lactotransferrin. Biochim. Biophys. Acta., 1980, 629, 399-408.
35. Redwan el, R. M.; Tabll, A. Camel lactoferrin markedly inhibits hepatitis C virus genotype 4 infection of human peripheral blood leukocytes. J. Immunoassay Immunochem., 2007, 28, 267-277.
36. Al-Majali, A. M.; Ismail, Z. B.; Al-Hami, Y.; Nour, A. Y. Lactoferrin concentration in milk from camels (Camelus dromedarius) with and without subclinical mastitis. Intern. J. Appl. Res. Vet. Med., 2007, 5, 120-124.
37. El-Hatmi, H.; Levieux, A.; Levieux, D. Camel (Camelus dromedarius) immunoglobulin G, alpha-lactalbumin, serum albumin and lactoferrin in colostrum and milk during the early post partum period. J. Dairy Res., 2006, 73, 288-293.
38. Khan, J. A.; Kumar, P.; Paramasivam, M.; Yadav, R. S.; Sahani, M. S.; Sharma, S.; Srinivasan, A.; Singh, T. P. Camel lactoferrin, a transferrin-cum-lactoferrin: crystal structure of camel apolactoferrin at 2. 6 A resolution and structural basis of its dual role. J. Mol. Biol., 2001, 309, 751-761.
39. Moore, S. A.; Anderson, B. F.; Groom, C. R.; Haridas, M.; Baker, E. N. Three-dimensional structure of diferric bovine lactoferrin at 2. 8 A resolution. J. Mol. Biol., 1997, 274, 222-236.
40. Steijns, J. M.; van Hooijdonk, A. C. Occurrence, structure, biochemical properties and technological characteristics of lactoferrin. Br. J. Nutr., 2000, 84(Suppl 1), S11-17.
41. Baker, H. M.; Baker, E. N. Lactoferrin and iron: structural and dynamic aspects of binding and release. Biometals, 2004, 17, 209-216.
42. Anderson, B. F.; Baker, H. M.; Norris, G. E.; Rice, D. W.; Baker, E. N. Structure of human lactoferrin: crystallographic structure analysis and refinement at 2. 8 A resolution. J. Mol. Biol., 1989, 209, 711-734.
43. Jameson, G. B.; Anderson, B. F.; Norris, G. E.; Thomas, D. H.; Baker, E. N. Structure of human apolactoferrin at 2. 0 A resolution. Refinement and analysis of ligand-induced conformational change. Acta. Crystallogr. D Biol. Crystallogr., 1998, 54, 1319-1335.
44. Shatsky, M.; Nussinov, R.; Wolfson, H. J. A method for simultaneous alignment of multiple protein structures. Proteins, 2004, 56, 143-156.
45. Dunker, A. K.; Obradovic, Z.; Romero, P.; Garner, E. C.; Brown, C. J. Intrinsic protein disorder in complete genomes. Genome Inform Ser Workshop Genome Inform, 2000, 11, 161-171.
46. Uversky, V. N. The mysterious unfoldome: structureless, underappreciated, yet vital part of any given proteome. J. Biomed. Biotechnol., 2010, 2010, 568068.
47. Ward, J. J.; Sodhi, J. S.; McGuffin, L. J.; Buxton, B. F.; Jones, D. T. Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. J. Mol. Biol., 2004, 337, 635-645.
48. Dunker, A. K.; Lawson, J. D.; Brown, C. J.; Williams, R. M.; Romero, P.; Oh, J. S.; Oldfield, C. J.; Campen, A. M.; Ratliff, C. M.; Hipps, K. W.; Ausio, J.; Nissen, M. S.; Reeves, R.; Kang, C.; Kissinger, C. R.; Bailey, R. W.; Griswold, M. D.; Chiu, W.; Garner, E. C.; Obradovic, Z. Intrinsically disordered protein. J. Mol. Graph. Model, 2001, 19, 26-59.
49. Uversky, V. N.; Dunker, A. K. Understanding protein non-folding. Biochim. Biophys. Acta., 2010, 1804, 1231-1264.
50. Wright, P. E.; Dyson, H. J. Intrinsically unstructured proteins: reassessing the protein structure-function paradigm. J. Mol. Biol., 1999, 293, 321-331.
51. Dunker, A. K.; Brown, C. J.; Lawson, J. D.; Iakoucheva, L. M.; Obradovic, Z. Intrinsic disorder and protein function. Biochemistry, 2002, 41, 6573-6582.
52. Tompa, P. Intrinsically unstructured proteins. Trends Biochem. Sci., 2002, 27, 527-533.
53. Dyson, H. J.; Wright, P. E. Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol., 2005, 6, 197-208.
54. Uversky, V. N.; Oldfield, C. J.; Dunker, A. K. Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling. J. Mol. Recognit., 2005, 18, 343-384.
55. Dunker, A. K.; Cortese, M. S.; Romero, P.; Iakoucheva, L. M.; Uversky, V. N. Flexible nets. The roles of intrinsic disorder in protein interaction networks. FEBS J., 2005, 272, 5129-5148.
56. Xie, H.; Vucetic, S.; Iakoucheva, L. M.; Oldfield, C. J.; Dunker, A. K.; Uversky, V. N.; Obradovic, Z. Functional anthology of intrinsic disorder. 1. Biological processes and functions of proteins with long disordered regions. J. Proteome Res., 2007, 6, 1882-1898.
57. Vucetic, S.; Xie, H.; Iakoucheva, L. M.; Oldfield, C. J.; Dunker, A. K.; Obradovic, Z.; Uversky, V. N. Functional anthology of intrinsic disorder. 2. Cellular components, domains, technical terms, developmental processes, and coding sequence diversities correlated with long disordered regions. J. Proteome Res., 2007, 6, 1899-1916.
58. Xie, H.; Vucetic, S.; Iakoucheva, L. M.; Oldfield, C. J.; Dunker, A. K.; Obradovic, Z.; Uversky, V. N. Functional anthology of intrinsic disorder. 3. Ligands, post-translational modifications, and diseases associated with intrinsically disordered proteins. J. Proteome Res., 2007, 6, 1917-1932.
59. Tompa, P. Intrinsically disordered proteins: a 10-year recap. Trends Biochem. Sci., 2012, 37, 509-516.
60. Uversky, V. N. A decade and a half of protein intrinsic disorder: biology still waits for physics. Protein Sci., 2013, 22, 693-724.
61. Iakoucheva, L. M.; Brown, C. J.; Lawson, J. D.; Obradovic, Z.; Dunker, A. K. Intrinsic disorder in cell-signaling and cancerassociated proteins. J. Mol. Biol., 2002, 323, 573-584.
62. Iakoucheva, L. M.; Radivojac, P.; Brown, C. J.; O'Connor, T. R.; Sikes, J. G.; Obradovic, Z.; Dunker, A. K. The importance of intrinsic disorder for protein phosphorylation. Nucleic Acids Res., 2004, 32, 1037-1049.
63. Yang, X. J. Multisite protein modification and intramolecular signaling. Oncogene, 2005, 24, 1653-1662.
64. Uversky, V. N. Intrinsic disorder-based protein interactions and their modulators. Curr. Pharm. Des., 2013, 19, 4191-4213.
65. Pejaver, V.; Hsu, W. L.; Xin, F.; Dunker, A. K.; Uversky, V. N.; Radivojac, P. The structural and functional signatures of proteins that undergo multiple events of post-translational modification. Protein Sci., 2014.
66. Hardiville, S.; Hoedt, E.; Mariller, C.; Benaissa, M.; Pierce, A. OGlcNAcylation/phosphorylation cycling at Ser10 controls both transcriptional activity and stability of delta-lactoferrin. J. Biol. Chem., 2010, 285, 19205-19218.
67. Romero, P. R.; Zaidi, S.; Fang, Y. Y.; Uversky, V. N.; Radivojac, P.; Oldfield, C. J.; Cortese, M. S.; Sickmeier, M.; LeGall, T.; Obradovic, Z.; Dunker, A. K. Alternative splicing in concert with protein intrinsic disorder enables increased functional diversity in multicellular organisms. Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 8390-8395.
68. Stamm, S.; Ben-Ari, S.; Rafalska, I.; Tang, Y.; Zhang, Z.; Toiber, D.; Thanaraj, T. A.; Soreq, H. Function of alternative splicing. Gene, 2005, 344, 1-20.
69. Brett, D.; Hanke, J.; Lehmann, G.; Haase, S.; Delbruck, S.; Krueger, S.; Reich, J.; Bork, P. EST comparison indicates 38% of human mRNAs contain possible alternative splice forms. FEBS Lett., 2000, 474, 83-86.
70. Johnson, J. M.; Castle, J.; Garrett-Engele, P.; Kan, Z.; Loerch, P. M.; Armour, C. D.; Santos, R.; Schadt, E. E.; Stoughton, R.; Shoemaker, D. D. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science, 2003, 302, 2141-2144.
71. Graveley, B. R. Alternative splicing: increasing diversity in the proteomic world. Trends Genet., 2001, 17, 100-107.
72. Minneman, K. P. Splice variants of G protein-coupled receptors. Mol. Interv., 2001, 1, 108-116.
73. Thai, T. H.; Kearney, J. F. Distinct and opposite activities of human terminal deoxynucleotidyltransferase splice variants. J. Immunol., 2004, 173, 4009-4019.
74. Scheper, W.; Zwart, R.; Baas, F. Alternative splicing in the Nterminus of Alzheimer's presenilin 1. Neurogenetics, 2004, 5, 223-227.
75. Buljan, M.; Chalancon, G.; Eustermann, S.; Wagner, G. P.; Fuxreiter, M.; Bateman, A.; Babu, M. M. Tissue-specific splicing of disordered segments that embed binding motifs rewires protein interaction networks. Mol. Cell, 2012, 46, 871-883.
76. Buljan, M.; Chalancon, G.; Dunker, A. K.; Bateman, A.; Balaji, S.; Fuxreiter, M.; Babu, M. M. Alternative splicing of intrinsically disordered regions and rewiring of protein interactions. Curr. Opin. Struct. Biol., 2013, 23, 443-450.
77. Kim, B.; Kang, S.; Kim, S. J. Genome-wide pathway analysis reveals different signaling pathways between secreted lactoferrin and intracellular delta-lactoferrin. PLoS One, 2013, 8, e55338.
78. Huang, J. M.; Wang, Z. Y.; Ju, Z. H.; Wang, C. F.; Li, Q. L.; Sun, T.; Hou, Q. L.; Hang, S. Q.; Hou, M. H.; Zhong, J. F. Two splice variants of the bovine lactoferrin gene identified in Staphylococcus aureus isolated from mastitis in dairy cattle. Genet. Mol. Res., 2011, 10, 3199-3203.
79. Vorland, L. H. Lactoferrin: a multifunctional glycoprotein. APMIS, 1999, 107, 971-981.
80. Baveye, S.; Elass, E.; Mazurier, J.; Spik, G.; Legrand, D. Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin. Chem. Lab. Med., 1999, 37, 281-286.
81. Weinberg, E. D. Human lactoferrin: a novel therapeutic with broad spectrum potential. J. Pharm. Pharmacol., 2001, 53, 1303-1310.
82. Orsi, N. The antimicrobial activity of lactoferrin: current status and perspectives. Biometals, 2004, 17, 189-196.
83. Bullen, J. J. Iron-binding proteins in milk and resistance to Escherichia coli infection in infants. Postgrad. Med. J., 1975, 51 suppl 3, 67-70.
84. Bullen, J. J. Iron-binding proteins in milk and resistance to Escherichia coli infection in infants. Proc. R. Soc. Med., 1972, 65, 1086.
85. Bullen, J. J.; Rogers, H. J.; Leigh, L. Iron-binding proteins in milk and resistance to Escherichia coli infection in infants. Br. Med. J., 1972, 1, 69-75.
86. Ochoa, T. J.; Cleary, T. G. Effect of lactoferrin on enteric pathogens. Biochimie., 2009, 91, 30-34.
87. Manzoni, P.; Decembrino, L.; Stolfi, I.; Pugni, L.; Rinaldi, M.; Cattani, S.; Romeo, M. G.; Messner, H.; Laforgia, N.; Vagnarelli, F.; Memo, L.; Bordignon, L.; Saia, O. S.; Maule, M.; Gallo, E.; Mostert, M.; Magnani, C.; Quercia, M.; Bollani, L.; Pedicino, R.; Renzullo, L.; Betta, P.; Ferrari, F.; Magaldi, R.; Mosca, F.; Stronati, M.; Farina, D. Lactoferrin and prevention of late-onset sepsis in the pre-term neonates. Early Hum. Dev., 2010, 86(Suppl 1), 59-61.
88. Yen, C. C.; Shen, C. J.; Hsu, W. H.; Chang, Y. H.; Lin, H. T.; Chen, H. L.; Chen, C. M. Lactoferrin: an iron-binding antimicrobial protein against Escherichia coli infection. Biometals, 2011, 24, 585-594.
89. Morgenthau, A.; Pogoutse, A.; Adamiak, P.; Moraes, T. F.; Schryvers, A. B. Bacterial receptors for host transferrin and lactoferrin: molecular mechanisms and role in host-microbe interactions. Future Microbiol., 2013, 8, 1575-1585.
90. Artym, J.; Zimecki, M. Milk-derived proteins and peptides in clinical trials. Postepy. Hig. Med. Dosw. (Online), 2013, 67, 800-816.
91. Liu, B.; Newburg, D. S. Human milk glycoproteins protect infants against human pathogens. Breastfeed Med., 2013, 8, 354-362.
92. Ammons, M. C.; Copie, V. Mini-review: Lactoferrin: a bioinspired, anti-biofilm therapeutic. Biofouling, 2013, 29, 443-455.
93. Turin, C. G.; Ochoa, T. J. The Role of Maternal Breast Milk in Preventing Infantile Diarrhea in the Developing World. Curr. Trop. Med. Rep., 2014, 1, 97-105.
94. Yoo, Y. C.; Watanabe, S.; Watanabe, R.; Hata, K.; Shimazaki, K.; Azuma, I. Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn. J. Cancer Res., 1997, 88, 184-190.
95. Legrand, D.; Elass, E.; Carpentier, M.; Mazurier, J. Lactoferrin: a modulator of immune and inflammatory responses. Cell Mol. Life Sci., 2005, 62, 2549-2559.
96. Legrand, D. Lactoferrin, a key molecule in immune and inflammatory processes. Biochem. Cell Biol., 2012, 90, 252-268.
97. Baker, E. N.; Baker, H. M. A structural framework for understanding the multifunctional character of lactoferrin. Biochimie., 2009, 91, 3-10.
98. Baker, E. N. Lactoferrin: a multi-tasking protein par excellence. Cell Mol. Life Sci., 2005, 62, 2529-2530.
99. Baker, E. N.; Baker, H. M. Molecular structure, binding properties and dynamics of lactoferrin. Cell Mol. Life Sci., 2005, 62, 2531-2539.
100. Nishiya, K.; Horwitz, D. A. Contrasting effects of lactoferrin on human lymphocyte and monocyte natural killer activity and antibody-dependent cell-mediated cytotoxicity. J. Immunol., 1982, 129, 2519-2523.
101. McCormick, J. A.; Markey, G. M.; Morris, T. C. Lactoferrininducible monocyte cytotoxicity for K562 cells and decay of natural killer lymphocyte cytotoxicity. Clin. Exp. Immunol., 1991, 83, 154-156.
102. Takayama, Y.; Aoki, R. Roles of lactoferrin on skin wound healing. Biochem. Cell Biol., 2012, 90, 497-503.
103. Yi, M.; Kaneko, S.; Yu, D. Y.; Murakami, S. Hepatitis C virus envelope proteins bind lactoferrin. J. Virol., 1997, 71, 5997-6002.
104. Ikeda, M.; Sugiyama, K.; Tanaka, T.; Tanaka, K.; Sekihara, H.; Shimotohno, K.; Kato, N. Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem. Biophys. Res. Commun., 1998, 245, 549-553.
105. Farnaud, S.; Evans, R. W. Lactoferrin-a multifunctional protein with antimicrobial properties. Mol. Immunol., 2003, 40, 395-405.
106. Yuan, L.; Saif, L. J. Induction of mucosal immune responses and protection against enteric viruses: rotavirus infection of gnotobiotic pigs as a model. Vet. Immunol. Immunopathol., 2002, 87, 147-160.
107. Valenti, P.; Antonini, G. Lactoferrin: an important host defence against microbial and viral attack. Cell Mol. Life Sci., 2005, 62, 2576-2587.
108. Giansanti, F.; Rossi, P.; Massucci, M. T.; Botti, D.; Antonini, G.; Valenti, P.; Seganti, L. Antiviral activity of ovotransferrin discloses an evolutionary strategy for the defensive activities of lactoferrin. Biochem. Cell Biol., 2002, 80, 125-130.
109. van der Strate, B. W.; Beljaars, L.; Molema, G.; Harmsen, M. C.; Meijer, D. K. Antiviral activities of lactoferrin. Antiviral Res., 2001, 52, 225-239.
110. Seganti, L.; Di Biase, A. M.; Marchetti, M.; Pietrantoni, A.; Tinari, A.; Superti, F. Antiviral activity of lactoferrin towards naked viruses. Biometals, 2004, 17, 295-299.
111. Berkhout, B.; Floris, R.; Recio, I.; Visser, S. The antiviral activity of the milk protein lactoferrin against the human immunodeficiency virus type 1. Biometals, 2004, 17, 291-294.
112. Tomita, M.; Wakabayashi, H.; Shin, K.; Yamauchi, K.; Yaeshima, T.; Iwatsuki, K. Twenty-five years of research on bovine lactoferrin applications. Biochimie., 2009, 91, 52-57.
113. Berlutti, F.; Pantanella, F.; Natalizi, T.; Frioni, A.; Paesano, R.; Polimeni, A.; Valenti, P. Antiviral properties of lactoferrin-a natural immunity molecule. Molecules, 2011, 16, 6992-7018.
114. Thibaut, H. J.; De Palma, A. M.; Neyts, J. Combating enterovirus replication: state-of-the-art on antiviral research. Biochem. Pharmacol., 2012, 83, 185-192.
115. Harmsen, M. C.; Swart, P. J.; de Bethune, M. P.; Pauwels, R.; De Clercq, E.; The, T. H.; Meijer, D. K. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J. Infect. Dis., 1995, 172, 380-388.
116. Hasegawa, K.; Motsuchi, W.; Tanaka, S.; Dosako, S. Inhibition with lactoferrin of in vitro infection with human herpes virus. Jpn. J. Med. Sci. Biol., 1994, 47, 73-85.
117. El-Fakharany, E. M.; Sanchez, L.; Al-Mehdar, H. A.; Redwan, E. M. Effectiveness of human, camel, bovine and sheep lactoferrin on the hepatitis C virus cellular infectivity: comparison study. Virol. J., 2013, 10, 199.
118. Szklarczyk, D.; Franceschini, A.; Kuhn, M.; Simonovic, M.; Roth, A.; Minguez, P.; Doerks, T.; Stark, M.; Muller, J.; Bork, P.; Jensen, L. J.; von Mering, C. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res., 2011, 39, D561-568.
119. Ashby, B.; Garrett, Q.; Willcox, M. Bovine lactoferrin structures promoting corneal epithelial wound healing in vitro. Invest. Ophthalmol. Vis. Sci., 2011, 52, 2719-2726.
120. Wagoner, M. D. Chemical injuries of the eye: current concepts in pathophysiology and therapy. Surv. Ophthalmol., 1997, 41, 275-313.
121. Merle, H.; Gerard, M.; Schrage, N. Ocular burns. J. Fr. Ophtalmol., 2008, 31, 723-734.
122. Brodovsky, S. C.; McCarty, C. A.; Snibson, G.; Loughnan, M.; Sullivan, L.; Daniell, M.; Taylor, H. R. Management of alkali burns: an 11-year retrospective review. Ophthalmology, 2000, 107, 1829-1835.
123. Suzuki, K.; Saito, J.; Yanai, R.; Yamada, N.; Chikama, T.; Seki, K.; Nishida, T. Cell-matrix and cell-cell interactions during corneal epithelial wound healing. Prog. Retin. Eye Res., 2003, 22, 113-133.
124. Lu, L.; Reinach, P. S.; Kao, W. W. Corneal epithelial wound healing. Exp. Biol. Med. (Maywood), 2001, 226, 653-664.
125. Pattamatta, U.; Willcox, M.; Stapleton, F.; Cole, N.; Garrett, Q. Bovine lactoferrin stimulates human corneal epithelial alkali wound healing in vitro. Invest. Ophthalmol. Vis. Sci., 2009, 50, 1636-1643.
126. Naidu, A. S. Lactoferrin, in Natural Food Antimicrobial Systems, Naidu, A. S., Editor. 2000, CRC Press: Boca Rton, London, New York, Washngton D. C. p. 28-113.
127. Bellamy, W.; Takase, M.; Yamauchi, K.; Wakabayashi, H.; Kawase, K.; Tomita, M. Identification of the bactericidal domain of lactoferrin. Biochim. Biophys. Acta., 1992, 1121, 130-136.
128. Dionysius, D. A.; Milne, J. M. Antibacterial peptides of bovine lactoferrin: purification and characterization. J. Dairy Sci., 1997, 80, 667-674.
129. Hoek, K. S.; Milne, J. M.; Grieve, P. A.; Dionysius, D. A.; Smith, R. Antibacterial activity in bovine lactoferrin-derived peptides. Antimicrob. Agents Chemother., 1997, 41, 54-59.
130. Hwang, P. M.; Zhou, N.; Shan, X.; Arrowsmith, C. H.; Vogel, H. J. Three-dimensional solution structure of lactoferricin B, an antimicrobial peptide derived from bovine lactoferrin. Biochemistry, 1998, 37, 4288-4298.
131. Hunter, H. N.; Demcoe, A. R.; Jenssen, H.; Gutteberg, T. J.; Vogel, H. J. Human lactoferricin is partially folded in aqueous solution and is better stabilized in a membrane mimetic solvent. Antimicrob. Agents Chemother., 2005, 49, 3387-3395.
132. Gifford, J. L.; Hunter, H. N.; Vogel, H. J. Lactoferricin: a lactoferrinderived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol. Life Sci., 2005, 62, 2588-2598.
133. Bellamy, W.; Wakabayashi, H.; Takase, M.; Kawase, K.; Shimamura, S.; Tomita, M. Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Med. Microbiol. Immunol., 1993, 182, 97-105.
134. Epand, R. M.; Vogel, H. J. Diversity of antimicrobial peptides and their mechanisms of action. Biochim. Biophys. Acta., 1999, 1462, 11-28.
135. Groenink, J.; Walgreen-Weterings, E.; van 't Hof, W.; Veerman, E. C.; Nieuw Amerongen, A. V. Cationic amphipathic peptides, derived from bovine and human lactoferrins, with antimicrobial activity against oral pathogens. FEMS Microbiol. Lett., 1999, 179, 217-222.
136. Ellison, R. T., 3rd; Giehl, T. J.; LaForce, F. M. Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. Infect. Immun., 1988, 56, 2774-2781.
137. Reite, B.; Oram, J. D. Bacterial inhibitors in milk and other biological fluids. Nature, 1967, 216, 328-330.
138. Arnold, R. R.; Cole, M. F.; McGhee, J. R. A bactericidal effect for human lactoferrin. Science, 1977, 197, 263-265.
139. van Berkel, P. H.; Geerts, M. E.; van Veen, H. A.; Mericskay, M.; de Boer, H. A.; Nuijens, J. H. N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA. Biochem. J., 1997, 328(Pt 1), 145-151.
140. Majerle, A.; Kidric, J.; Jerala, R. Enhancement of antibacterial and lipopolysaccharide binding activities of a human lactoferrin peptide fragment by the addition of acyl chain. J. Antimicrob. Chemother., 2003, 51, 1159-1165.
141. Erdei, J.; Forsgren, A.; Naidu, A. S. Lactoferrin binds to porins OmpF and OmpC in Escherichia coli. Infect. Immun., 1994, 62, 1236-1240.
142. Sallmann, F. R.; Baveye-Descamps, S.; Pattus, F.; Salmon, V.; Branza, N.; Spik, G.; Legrand, D. Porins OmpC and PhoE of Escherichia coli as specific cell-surface targets of human lactoferrin. Binding characteristics and biological effects. J. Biol. Chem., 1999, 274, 16107-16114.
143. Gonzalez-Chavez, S. A.; Arevalo-Gallegos, S.; Rascon-Cruz, Q. Lactoferrin: structure, function and applications. Int. J. Antimicrob. Agents, 2009, 33, 301 e301-308.
144. Chapple, D. S.; Mason, D. J.; Joannou, C. L.; Odell, E. W.; Gant, V.; Evans, R. W. Structure-function relationship of antibacterial synthetic peptides homologous to a helical surface region on human lactoferrin against Escherichia coli serotype O111. Infect. Immun., 1998, 66, 2434-2440.
145. Velliyagounder, K.; Kaplan, J. B.; Furgang, D.; Legarda, D.; Diamond, G.; Parkin, R. E.; Fine, D. H. One of two human lactoferrin variants exhibits increased antibacterial and transcriptional activation activities and is associated with localized juvenile periodontitis. Infect. Immun., 2003, 71, 6141-6147.
146. Diamond, G.; Kaiser, V.; Rhodes, J.; Russell, J. P.; Bevins, C. L. Transcriptional regulation of beta-defensin gene expression in tracheal epithelial cells. Infect. Immun., 2000, 68, 113-119.
147. Diamond, G.; Russell, J. P.; Bevins, C. L. Inducible expression of an antibiotic peptide gene in lipopolysaccharide-challenged tracheal epithelial cells. Proc. Natl. Acad. Sci. U. S. A., 1996, 93, 5156-5160.
148. Zambon, J. J. Actinobacillus actinomycetemcomitans in human periodontal disease. J. Clin. Periodontol., 1985, 12, 1-20.
149. Friedman, S. A.; Mandel, I. D.; Herrera, M. S. Lysozyme and lactoferrin quantitation in the crevicular fluid. J. Periodontol., 1983, 54, 347-350.
150. Groenink, J.; Walgreen-Weterings, E.; Nazmi, K.; Bolscher, J. G.; Veerman, E. C.; van Winkelhoff, A. J.; Nieuw Amerongen, A. V. Salivary lactoferrin and low-Mr mucin MG2 in Actinobacillus actinomycetemcomitans-associated periodontitis. J. Clin. Periodontol., 1999, 26, 269-275.
151. Fine, D. H.; Furgang, D.; Beydouin, F. Lactoferrin iron levels are reduced in saliva of patients with localized aggressive periodontitis. J. Periodontol., 2002, 73, 624-630.
152. Sioson, P. B.; Furgang, D.; Steinberg, L. M.; Fine, D. H. Proximal caries in juvenile periodontitis patients. J. Periodontol., 2000, 71, 710-716.
153. de Lillo, A.; Quiros, L. M.; Fierro, J. F. Relationship between antibacterial activity and cell surface binding of lactoferrin in species of genus Micrococcus. FEMS Microbiol. Lett., 1997, 150, 89-94.
154. Stuart, J.; Norrell, S.; Harrington, J. P. Kinetic effect of human lactoferrin on the growth of Escherichia coli 0111. Int. J. Biochem., 1984, 16, 1043-1047.
155. Conesa, C.; Sanchez, L.; Rota, C.; Perez, M. D.; Calvo, M.; Farnaud, S.; Evans, R. W. Isolation of lactoferrin from milk of different species: calorimetric and antimicrobial studies. Comp. Biochem. Physiol. B Biochem. Mol. Biol., 2008, 150, 131-139.
156. Shin, K.; Yamauchi, K.; Teraguchi, S.; Hayasawa, H.; Tomita, M.; Otsuka, Y.; Yamazaki, S. Antibacterial activity of bovine lactoferrin and its peptides against enterohaemorrhagic Escherichia coli O157: H7. Lett. Appl. Microbiol., 1998, 26, 407-411.
157. Dionysius, D. A.; Grieve, P. A.; Milne, J. M. Forms of lactoferrin: their antibacterial effect on enterotoxigenic Escherichia coli. J. Dairy Sci., 1993, 76, 2597-2600.
158. Fine, D. H.; Furgang, D. Lactoferrin iron levels affect attachment of Actinobacillus actinomycetemcomitans to buccal epithelial cells. J. Periodontol., 2002, 73, 616-623.
159. Hendrixson, D. R.; Qiu, J.; Shewry, S. C.; Fink, D. L.; Petty, S.; Baker, E. N.; Plaut, A. G.; St Geme, J. W. 3rd, Human milk lactoferrin is a serine protease that cleaves Haemophilus surface proteins at arginine-rich sites. Mol. Microbiol., 2003, 47, 607-617.
160. Rose, J. E.; Meyer, D. H.; Fives-Taylor, P. M. Aae, an autotransporter involved in adhesion of Actinobacillus actinomycetemcomitans to epithelial cells. Infect. Immun., 2003, 71, 2384-2393.
161. Naidu, A. S.; Arnold, R. R. Lactoferrin interaction with salmonellae potentiates antibiotic susceptibility in vitro. Diagn. Microbiol. Infect. Dis., 1994, 20, 69-75.
162. Salamah, A. A.; al-Obaidi, A. S. Effect of some physical and chemical factors on the bactericidal activity of human lactoferrin and transferrin against Yersinia pseudotuberculosis. New Microbiol., 1995, 18, 275-281.
163. Paulsson, M. A.; Svensson, U.; Kishore, A. R.; Naidu, A. S. Thermal behavior of bovine lactoferrin in water and its relation to bacterial interaction and antibacterial activity. J. Dairy Sci., 1993, 76, 3711-3720.
164. Sinha, M.; Kaushik, S.; Kaur, P.; Sharma, S.; Singh, T. P. Antimicrobial lactoferrin peptides: the hidden players in the protective function of a multifunctional protein. Int. J. Pept., 2013, 2013, 390230.
165. Puknun, A.; Bolscher, J. G.; Nazmi, K.; Veerman, E. C.; Tungpradabkul, S.; Wongratanacheewin, S.; Kanthawong, S.; Taweechaisupapong, S. A heterodimer comprised of two bovine lactoferrin antimicrobial peptides exhibits powerful bactericidal activity against Burkholderia pseudomallei. World J. Microbiol. Biotechnol., 2013, 29, 1217-1224.
166. Lizzi, A. R.; Carnicelli, V.; Clarkson, M. M.; Di Giulio, A.; Oratore, A. Lactoferrin derived peptides: mechanisms of action and their perspectives as antimicrobial and antitumoral agents. Mini Rev. Med. Chem., 2009, 9, 687-695.
167. Enrique, M.; Manzanares, P.; Yuste, M.; Martinez, M.; Valles, S.; Marcos, J. F. Selectivity and antimicrobial action of bovine lactoferrin derived peptides against wine lactic acid bacteria. Food Microbiol., 2009, 26, 340-346.
168. van der Kraan, M. I.; van Marle, J.; Nazmi, K.; Groenink, J.; van 't Hof, W.; Veerman, E. C.; Bolscher, J. G.; Nieuw Amerongen, A. V. Ultrastructural effects of antimicrobial peptides from bovine lactoferrin on the membranes of Candida albicans and Escherichia coli. Peptides, 2005, 26, 1537-1542.
169. Tomita, M.; Takase, M.; Wakabayashi, H.; Bellamy, W. Antimicrobial peptides of lactoferrin. Adv. Exp. Med. Biol., 1994, 357, 209-218.
170. Andersen, J. H.; Jenssen, H.; Gutteberg, T. J. Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. Antiviral Res., 2003, 58, 209-215.
171. Andersen, J. H.; Jenssen, H.; Sandvik, K.; Gutteberg, T. J. Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparan sulphate at the cell surface. J. Med. Virol., 2004, 74, 262-271.
172. Jenssen, H. Anti herpes simplex virus activity of lactoferrin/lactoferricin-an example of antiviral activity of antimicrobial protein/peptide. Cell Mol. Life Sci., 2005, 62, 3002-3013.
173. Marchetti, M.; Longhi, C.; Conte, M. P.; Pisani, S.; Valenti, P.; Seganti, L. Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells. Antiviral Res., 1996, 29, 221-231.
174. Marchetti, M.; Trybala, E.; Superti, F.; Johansson, M.; Bergstrom, T. Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans. Virology, 2004, 318, 405-413.
175. Arnold, D.; Di Biase, A. M.; Marchetti, M.; Pietrantoni, A.; Valenti, P.; Seganti, L.; Superti, F. Antiadenovirus activity of milk proteins: lactoferrin prevents viral infection. Antiviral Res., 2002, 53, 153-158.
176. Puddu, P.; Borghi, P.; Gessani, S.; Valenti, P.; Belardelli, F.; Seganti, L. Antiviral effect of bovine lactoferrin saturated with metal ions on early steps of human immunodeficiency virus type 1 infection. Int. J. Biochem. Cell Biol., 1998, 30, 1055-1062.
177. Swart, P. J.; Harmsen, M. C.; Kuipers, M. E.; Van Dijk, A. A.; Van Der Strate, B. W.; Van Berkel, P. H.; Nuijens, J. H.; Smit, C.; Witvrouw, M.; De Clercq, E.; de Bethune, M. P.; Pauwels, R.; Meijer, D. K. Charge modification of plasma and milk proteins results in antiviral active compounds. J. Pept. Sci., 1999, 5, 563-576.
178. Ikeda, M.; Nozaki, A.; Sugiyama, K.; Tanaka, T.; Naganuma, A.; Tanaka, K.; Sekihara, H.; Shimotohno, K.; Saito, M.; Kato, N. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res., 2000, 66, 51-63.
179. Hara, K.; Ikeda, M.; Saito, S.; Matsumoto, S.; Numata, K.; Kato, N.; Tanaka, K.; Sekihara, H. Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol. Res., 2002, 24, 228.
180. Li, S.; Zhou, H.; Huang, G.; Liu, N. Inhibition of HBV infection by bovine lactoferrin and iron-, zinc-saturated lactoferrin. Med. Microbiol. Immunol., 2009, 198, 19-25.
181. Petrova, M.; Kamburov, V. Breastfeeding and chronic HBV infection: clinical and social implications. World J. Gastroenterol., 2010, 16, 5042-5046.
182. Andersen, J. H.; Osbakk, S. A.; Vorland, L. H.; Traavik, T.; Gutteberg, T. J. Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts. Antiviral Res., 2001, 51, 141-149.
183. Marchetti, M.; Superti, F.; Ammendolia, M. G.; Rossi, P.; Valenti, P.; Seganti, L. Inhibition of poliovirus type 1 infection by iron-, manganese-and zinc-saturated lactoferrin. Med. Microbiol. Immunol., 1999, 187, 199-204.
184. McCann, K. B.; Lee, A.; Wan, J.; Roginski, H.; Coventry, M. J. The effect of bovine lactoferrin and lactoferricin B on the ability of feline calicivirus (a norovirus surrogate) and poliovirus to infect cell cultures. J. Appl. Microbiol., 2003, 95, 1026-1033.
185. Murphy, M. E.; Kariwa, H.; Mizutani, T.; Yoshimatsu, K.; Arikawa, J.; Takashima, I. In vitro antiviral activity of lactoferrin and ribavirin upon hantavirus. Arch. Virol., 2000, 145, 1571-1582.
186. Hardestam, J.; Petterson, L.; Ahlm, C.; Evander, M.; Lundkvist, A.; Klingstrom, J. Antiviral effect of human saliva against hantavirus. J. Med. Virol., 2008, 80, 2122-2126.
187. Murphy, M. E.; Kariwa, H.; Mizutani, T.; Tanabe, H.; Yoshimatsu, K.; Arikawa, J.; Takashima, I. Characterization of in vitro and in vivo antiviral activity of lactoferrin and ribavirin upon hantavirus. J. Vet. Med. Sci., 2001, 63, 637-645.
188. Lin, T. Y.; Chu, C.; Chiu, C. H. Lactoferrin inhibits enterovirus 71 infection of human embryonal rhabdomyosarcoma cells in vitro. J. Infect. Dis., 2002, 186, 1161-1164.
189. Lu, L.; Shen, R. N.; Zhou, S. Z.; Srivastava, C.; Harrington, M.; Miyazawa, K.; Wu, B.; Lin, Z. H.; Ruscetti, S.; Broxmeyer, H. E. Synergistic effect of human lactoferrin and recombinant murine interferon-gamma on disease progression in mice infected with the polycythemia-inducing strain of the Friend virus complex. Int. J. Hematol., 1991, 54, 117-124.
190. Lu, L.; Hangoc, G.; Oliff, A.; Chen, L. T.; Shen, R. N.; Broxmeyer, H. E. Protective influence of lactoferrin on mice infected with the polycythemia-inducing strain of Friend virus complex. Cancer Res., 1987, 47, 4184-4188.
191. Portelli, J.; Gordon, A.; May, J. T. Effect of compounds with antibacterial activities in human milk on respiratory syncytial virus and cytomegalovirus in vitro. J. Med. Microbiol., 1998, 47, 1015-1018.
192. Sano, H.; Nagai, K.; Tsutsumi, H.; Kuroki, Y. Lactoferrin and surfactant protein A exhibit distinct binding specificity to F protein and differently modulate respiratory syncytial virus infection. Eur. J. Immunol., 2003, 33, 2894-2902.
193. Yamamoto, H.; Ura, Y.; Tanemura, M.; Koyama, A.; Takano, S.; Uematsu, J.; Kawano, M.; Tsurudome, M.; O'Brien, M.; Komada, H. Inhibitory effect of bovine lactoferrin on human parainfluenza virus type 2 infection. J. Health Sci., 2010, 54, 613-617.
194. Waarts, B. L.; Aneke, O. J.; Smit, J. M.; Kimata, K.; Bittman, R.; Meijer, D. K.; Wilschut, J. Antiviral activity of human lactoferrin: inhibition of alphavirus interaction with heparan sulfate. Virology, 2005, 333, 284-292.
195. Drobni, P.; Naslund, J.; Evander, M. Lactoferrin inhibits human papillomavirus binding and uptake in vitro. Antiviral Res., 2004, 64, 63-68.
196. Mistry, N.; Drobni, P.; Naslund, J.; Sunkari, V. G.; Jenssen, H.; Evander, M. The anti-papillomavirus activity of human and bovine lactoferricin. Antiviral Res., 2007, 75, 258-265.
197. Longhi, G.; Pietropaolo, V.; Mischitelli, M.; Longhi, C.; Conte, M. P.; Marchetti, M.; Tinari, A.; Valenti, P.; Degener, A. M.; Seganti, L.; Superti, F. Lactoferrin inhibits early steps of human BK polyomavirus infection. Antiviral Res., 2006, 72, 145-152.
198. Degener, A. M.; Longhi, G.; Mischitelli, M.; Longhi, C.; Conte, M. P.; Valenti, P.; Seganti, L.; Marchetti, M.; Superti, F. Lactoferrin inhibits human BK polyomavirus adsorption to Vero cells. Biochem. Cell Biol., 2006, 84, 389-389.
199. Superti, F.; Ammendolia, M. G.; Valenti, P.; Seganti, L. Antirotaviral activity of milk proteins: lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT-29. Med. Microbiol. Immunol., 1997, 186, 83-91.
200. Superti, F.; Siciliano, R.; Rega, B.; Giansanti, F.; Valenti, P.; Antonini, G. Involvement of bovine lactoferrin metal saturation, sialic acid and protein fragments in the inhibition of rotavirus infection. Biochim. Biophys. Acta., 2001, 1528, 107-115.
201. Manns, M. P.; McHutchison, J. G.; Gordon, S. C.; Rustgi, V. K.; Shiffman, M.; Reindollar, R.; Goodman, Z. D.; Koury, K.; Ling, M.; Albrecht, J. K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001, 358, 958-965.
202. Jaeckel, E.; Cornberg, M.; Wedemeyer, H.; Santantonio, T.; Mayer, J.; Zankel, M.; Pastore, G.; Dietrich, M.; Trautwein, C.; Manns, M. P. Treatment of acute hepatitis C with interferon alfa-2b. N. Engl. J. Med., 2001, 345, 1452-1457.
203. Fried, M. W.; Shiffman, M. L.; Reddy, K. R.; Smith, C.; Marinos, G.; Goncales, F. L., Jr.; Haussinger, D.; Diago, M.; Carosi, G.; Dhumeaux, D.; Craxi, A.; Lin, A.; Hoffman, J.; Yu, J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med., 2002, 347, 975-982.
204. Abe, K.; Nozaki, A.; Tamura, K.; Ikeda, M.; Naka, K.; Dansako, H.; Hoshino, H. O.; Tanaka, K.; Kato, N. Tandem repeats of lactoferrin-derived anti-hepatitis C virus peptide enhance antiviral activity in cultured human hepatocytes. Microbiol. Immunol., 2007, 51, 117-125.
205. Azzam, H. S.; Goertz, C.; Fritts, M.; Jonas, W. B. Natural products and chronic hepatitis C virus. Liver Int., 2007, 27, 17-25.
206. Ueno, H.; Sato, T.; Yamamoto, S.; Tanaka, K.; Ohkawa, S.; Takagi, H.; Yokosuka, O.; Furuse, J.; Saito, H.; Sawaki, A.; Kasugai, H.; Osaki, Y.; Fujiyama, S.; Sato, K.; Wakabayashi, K.; Okusaka, T. Randomized, double-blind, placebo-controlled trial of bovine lactoferrin in patients with chronic hepatitis C. Cancer Sci., 2006, 97, 1105-1110.
207. Konishi, M.; Iwasa, M.; Yamauchi, K.; Sugimoto, R.; Fujita, N.; Kobayashi, Y.; Watanabe, S.; Teraguchi, S.; Adachi, Y.; Kaito, M. Lactoferrin inhibits lipid peroxidation in patients with chronic hepatitis C. Hepatol. Res., 2006, 36, 27-32.
208. Ishii, K.; Takamura, N.; Shinohara, M.; Wakui, N.; Shin, H.; Sumino, Y.; Ohmoto, Y.; Teraguchi, S.; Yamauchi, K. Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. Hepatol. Res., 2003, 25, 226-233.
209. Nozaki, A.; Ikeda, M.; Naganuma, A.; Nakamura, T.; Inudoh, M.; Tanaka, K.; Kato, N. Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein. J. Biol. Chem., 2003, 278, 10162-10173.
210. Legrand, D.; Elass, E.; Pierce, A.; Mazurier, J. Lactoferrin and host defence: an overview of its immuno-modulating and antiinflammatory properties. Biometals, 2004, 17, 225-229.
211. Bonkovsky, H. L. Iron as a comorbid factor in chronic viral hepatitis. Am. J. Gastroenterol., 2002, 97, 1-4.
212. Farinati, F.; Cardin, R.; De Maria, N.; Della Libera, G.; Marafin, C.; Lecis, E.; Burra, P.; Floreani, A.; Cecchetto, A.; Naccarato, R. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J. Hepatol., 1995, 22, 449-456.
213. Bonkovsky, H. L.; Banner, B. F.; Rothman, A. L. Iron and chronic viral hepatitis. Hepatology, 1997, 25, 759-768.
214. Iwasa, M.; Kaito, M.; Ikoma, J.; Takeo, M.; Imoto, I.; Adachi, Y.; Yamauchi, K.; Koizumi, R.; Teraguchi, S. Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype 1b. Am. J. Gastroenterol., 2002, 97, 766-767.
215. Tanaka, K.; Ikeda, M.; Nozaki, A.; Kato, N.; Tsuda, H.; Saito, S.; Sekihara, H. Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. Jpn. J. Cancer Res., 1999, 90, 367-371.
216. Kaito, M.; Iwasa, M.; Fujita, N.; Kobayashi, Y.; Kojima, Y.; Ikoma, J.; Imoto, I.; Adachi, Y.; Hamano, H.; Yamauchi, K. Effect of lactoferrin in patients with chronic hepatitis C: combination therapy with interferon and ribavirin. J. Gastroenterol. Hepatol., 2007, 22, 1894-1897.
217. Choo, Q. L.; Kuo, G.; Weiner, A. J.; Overby, L. R.; Bradley, D. W.; Houghton, M. Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science, 1989, 244, 359-362.
218. Kuo, G.; Choo, Q. L.; Alter, H. J.; Gitnick, G. L.; Redeker, A. G.; Purcell, R. H.; Miyamura, T.; Dienstag, J. L.; Alter, M. J.; Stevens, C. E.; et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science, 1989, 244, 362-364.
219. Shiratori, Y.; Kato, N.; Yokosuka, O.; Imazeki, F.; Hashimoto, E.; Hayashi, N.; Nakamura, A.; Asada, M.; Kuroda, H.; Tanaka, N.; Arakawa, Y.; Omata, M. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology, 1997, 113, 558-566.
220. McHutchison, J. G.; Gordon, S. C.; Schiff, E. R.; Shiffman, M. L.; Lee, W. M.; Rustgi, V. K.; Goodman, Z. D.; Ling, M. H.; Cort, S.; Albrecht, J. K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med., 1998, 339, 1485-1492.
221. Ishibashi, Y.; Takeda, K.; Tsukidate, N.; Miyazaki, H.; Ohira, K.; Dosaka-Akita, H.; Nishimura, M. Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C. Hepatol. Res., 2005, 32, 218-223.
222. Pileri, P.; Uematsu, Y.; Campagnoli, S.; Galli, G.; Falugi, F.; Petracca, R.; Weiner, A. J.; Houghton, M.; Rosa, D.; Grandi, G.; Abrignani, S. Binding of hepatitis C virus to CD81. Science, 1998, 282, 938-941.
223. Yolken, R. H.; Peterson, J. A.; Vonderfecht, S. L.; Fouts, E. T.; Midthun, K.; Newburg, D. S. Human milk mucin inhibits rotavirus replication and prevents experimental gastroenteritis. J. Clin. Invest., 1992, 90, 1984-1991.
224. Brock, J. Lactoferrin: a multifunctional immunoregulatory protein? Immunol. Today, 1995, 16, 417-419.
225. Ikeda, M.; Sugiyama, K.; Mizutani, T.; Tanaka, T.; Tanaka, K.; Shimotohno, K.; Kato, N. Hepatitis G virus replication in human cultured cells displaying susceptibility to hepatitis C virus infection. Biochem. Biophys. Res. Commun., 1997, 235, 505-508.
226. Ferri, C.; Monti, M.; La Civita, L.; Longombardo, G.; Greco, F.; Pasero, G.; Gentilini, P.; Bombardieri, S.; Zignego, A. L. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood, 1993, 82, 3701-3704.
227. Silvestri, F.; Pipan, C.; Barillari, G.; Zaja, F.; Fanin, R.; Infanti, L.; Russo, D.; Falasca, E.; Botta, G. A.; Baccarani, M. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood, 1996, 87, 4296-4301.
228. Leary, T. P.; Muerhoff, A. S.; Simons, J. N.; Pilot-Matias, T. J.; Erker, J. C.; Chalmers, M. L.; Schlauder, G. G.; Dawson, G. J.; Desai, S. M.; Mushahwar, I. K. Sequence and genomic organization of GBV-C: a novel member of the flaviviridae associated with human non-A-E hepatitis. J. Med. Virol., 1996, 48, 60-67.
229. Valenti, P.; Marchetti, M.; Superti, F.; Ammendolia, M. G.; Puddu, P.; Gessani, S.; Borghi, P.; Belardelli, F.; Antonini, G.; Seganti, L. Antiviral activity of lactoferrin, in Advances in lactoferrin research, Spik, G.; Legrand, D.; Mazurier, J.; Pierce, A.; Perraudin, J. P. Editors. 1998, Plenum Press: New York, N. Y. p. 199-203.
230. Meijer, D. K. F.; van Heeswijk, R. P. G.; Swart, P. J.; Beljaars, L.; Huisman, J. G.; Koenderman, A.; The, T. H.; Harmsen, M. C.; Floris, R.; van den Berg, J. J. M.; Smit, C.; Bakker, H.; van der Strate, B. W. A.; Kuipers, M. E.; Jansen, R. W.; Molema, G.; Berkhout, B. Charge-modified plasma and milk proteins that interfere with HIV and CMV/target cell binding and fusion, in Recent Research Developments in Antiviral Research, Pandalai, S. G. Editor. 2001, Transworld Research Network: Kerala, India. p. 81-115.
231. Byrnes, A. P.; Griffin, D. E. Binding of Sindbis virus to cell surface heparan sulfate. J. Virol., 1998, 72, 7349-7356.
232. Klimstra, W. B.; Ryman, K. D.; Johnston, R. E. Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor. J. Virol., 1998, 72, 7357-7366.
233. Bernard, K. A.; Klimstra, W. B.; Johnston, R. E. Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology, 2000, 276, 93-103.
234. Heil, M. L.; Albee, A.; Strauss, J. H.; Kuhn, R. J. An amino acid substitution in the coding region of the E2 glycoprotein adapts Ross River virus to utilize heparan sulfate as an attachment moiety. J. Virol., 2001, 75, 6303-6309.
235. Summerford, C.; Samulski, R. J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol., 1998, 72, 1438-1445.
236. Jackson, T.; Ellard, F. M.; Ghazaleh, R. A.; Brookes, S. M.; Blakemore, W. E.; Corteyn, A. H.; Stuart, D. I.; Newman, J. W.; King, A. M. Efficient infection of cells in culture by type O footand-mouth disease virus requires binding to cell surface heparan sulfate. J. Virol., 1996, 70, 5282-5287.
237. Sa-Carvalho, D.; Rieder, E.; Baxt, B.; Rodarte, R.; Tanuri, A.; Mason, P. W. Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J. Virol., 1997, 71, 5115-5123.
238. Birkmann, A.; Mahr, K.; Ensser, A.; Yaguboglu, S.; Titgemeyer, F.; Fleckenstein, B.; Neipel, F. Cell surface heparan sulfate is a receptor for human herpesvirus 8 and interacts with envelope glycoprotein K8. 1. J. Virol., 2001, 75, 11583-11593.
239. Shukla, D.; Spear, P. G. Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. J. Clin. Invest., 2001, 108, 503-510.
240. Patel, M.; Yanagishita, M.; Roderiquez, G.; Bou-Habib, D. C.; Oravecz, T.; Hascall, V. C.; Norcross, M. A. Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res. Hum. Retroviruses, 1993, 9, 167-174.
241. Goodfellow, I. G.; Sioofy, A. B.; Powell, R. M.; Evans, D. J. Echoviruses bind heparan sulfate at the cell surface. J. Virol., 2001, 75, 4918-4921.
242. Chen, Y.; Maguire, T.; Hileman, R. E.; Fromm, J. R.; Esko, J. D.; Linhardt, R. J.; Marks, R. M. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med., 1997, 3, 866-871.
243. Germi, R.; Crance, J. M.; Garin, D.; Guimet, J.; Lortat-Jacob, H.; Ruigrok, R. W.; Zarski, J. P.; Drouet, E. Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus. Virology, 2002, 292, 162-168.
244. Hilgard, P.; Stockert, R. Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes. Hepatology, 2000, 32, 1069-1077.
245. Trybala, E.; Roth, A.; Johansson, M.; Liljeqvist, J. A.; Rekabdar, E.; Larm, O.; Bergstrom, T. Glycosaminoglycan-binding ability is a feature of wild-type strains of herpes simplex virus type 1. Virology, 2002, 302, 413-419.
246. Smit, J. M.; Waarts, B. L.; Kimata, K.; Klimstra, W. B.; Bittman, R.; Wilschut, J. Adaptation of alphaviruses to heparan sulfate: interaction of Sindbis and Semliki forest viruses with liposomes containing lipid-conjugated heparin. J. Virol., 2002, 76, 10128-10137.
247. Berkhout, B.; van Wamel, J. L.; Beljaars, L.; Meijer, D. K.; Visser, S.; Floris, R. Characterization of the anti-HIV effects of native lactoferrin and other milk proteins and protein-derived peptides. Antiviral Res., 2002, 55, 341-355.
248. Pietrantoni, A.; Ammendolia, M. G.; Tinari, A.; Siciliano, R.; Valenti, P.; Superti, F. Bovine lactoferrin peptidic fragments involved in inhibition of Echovirus 6 in vitro infection. Antiviral Res., 2006, 69, 98-106.
249. Ammendolia, M. G.; Agamennone, M.; Pietrantoni, A.; Lannutti, F.; Siciliano, R. A.; De Giulio, B.; Amici, C.; Superti, F. Bovine lactoferrin-derived peptides as novel broad-spectrum inhibitors of influenza virus. Pathog. Glob. Health, 2012, 106, 12-19.
250. Spik, G.; Coddeville, B.; Montreuil, J. Comparative study of the primary structures of sero-, lacto-and ovotransferrin glycans from different species. Biochimie., 1988, 70, 1459-1469.
251. Florian, P. E.; Trif, M.; Evans, R. W.; Roeanu, A. An overview on the antiviral activity of lactoferrin. Rom. J. Biochem., 2009, 46, 187-197.
252. Siciliano, R.; Rega, B.; Marchetti, M.; Seganti, L.; Antonini, G.; Valenti, P. Bovine lactoferrin peptidic fragments involved in inhibition of herpes simplex virus type 1 infection. Biochem. Biophys. Res. Commun., 1999, 264, 19-23.
253. El-Fakharany, E. M.; Tabll, A.; Abd El-Wahab, A.; Haroun, B. M.; Redwan, E. M. Potential activity of camel milk-amylase and lactoferrin against hepatitis C virus infectivity in HepG2 and lymphocytes. Hepat. Mon., 2008, 8, 101-109.
254. Liao, Y.; El-Fakkarany, E.; Lonnerdal, B.; Redwan, E. M. Inhibitory effects of native and recombinant full-length camel lactoferrin and its N and C lobes on hepatitis C virus infection of Huh7. 5 cells. J. Med. Microbiol., 2012, 61, 375-383.
255. Tomita, M.; Bellamy, W.; Takase, M.; Yamauchi, K.; Wakabayashi, H.; Kawase, K. Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin. J. Dairy Sci., 1991, 74, 4137-4142.
256. Baker, E. N.; Baker, H. M.; Kidd, R. D. Lactoferrin and transferrin: functional variations on a common structural framework. Biochem. Cell Biol., 2002, 80, 27-34.
257. Sanchez, L.; Calvo, M.; Brock, J. H. Biological role of lactoferrin. Arch. Dis. Child, 1992, 67, 657-661.
258. Wu, H. F.; Monroe, D. M.; Church, F. C. Characterization of the glycosaminoglycan-binding region of lactoferrin. Arch. Biochem. Biophys., 1995, 317, 85-92.
259. El Yazidi-Belkoura, I.; Legrand, D.; Nuijens, J.; Slomianny, M. C.; van Berkel, P.; Spik, G. The binding of lactoferrin to glycosaminoglycans on enterocyte-like HT29-18-C1 cells is mediated through basic residues located in the N-terminus. Biochim. Biophys. Acta., 2001, 1568, 197-204.
260. Oates, M. E.; Romero, P.; Ishida, T.; Ghalwash, M.; Mizianty, M. J.; Xue, B.; Dosztanyi, Z.; Uversky, V. N.; Obradovic, Z.; Kurgan, L.; Dunker, A. K.; Gough, J. D(2)P(2): database of disordered protein predictions. Nucleic Acids Res., 2013, 41, D508-516.
261. Obradovic, Z.; Peng, K.; Vucetic, S.; Radivojac, P.; Dunker, A. K. Exploiting heterogeneous sequence properties improves prediction of protein disorder. Proteins, 2005, 61 Suppl 7, 176-182.
262. Obradovic, Z.; Peng, K.; Vucetic, S.; Radivojac, P.; Brown, C. J.; Dunker, A. K. Predicting intrinsic disorder from amino acid sequence. Proteins, 2003, 53(Suppl 6), 566-572.
263. Xue, B.; Dunbrack, R. L.; Williams, R. W.; Dunker, A. K.; Uversky, V. N. PONDR-FIT: a meta-predictor of intrinsically disordered amino acids. Biochim. Biophys. Acta., 2010, 1804, 996-1010.